After 40 years of living and travelling together, a writer considers a trip without his wife. He can't explain where he's going or why he can't bring her along.

In Georgia, more than 130,000 are currently living with Alzheimer's, which is expected to increase 46% over the next decade, according to the state Department of Public Health.

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.

Diseases like Alzheimer's and Parkinson's spread through the brain like a forest fire. A new study suggests how the fire starts.

The Georgia Alzheimer's Disease & Related Dementias Task Force has since 2014 sought ways to improve dementia research, awareness, training, and supportive care. 

Flemister, who died last week, was the first Black woman to serve as a special agent in the 1970s, but was forced out by racial discrimination. She spent the next three decades in the foreign service.

The Alzheimer’s Music Festival was started a decade ago by a musician who stepped back from his career in his mid 20s to care for his father, who was diagnosed with early onset Alzheimer’s. The 10th annual show is Saturday at Atlanta's Buckhead Theatre.

An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.

On the Monday Dec. 26 edition of Georgia Today: Where to recycle your Christmas tree, positive news for Alzheimer's patients, a look at the Savannah Bananas.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Researchers are launching a make-or-break study to test the conventional wisdom about what causes Alzheimer's disease.

This week’s Medical Minute, discusses the role of microvascular disease in the progression of Alzheimer’s.

Rather than treating patients in clinical trials with a specific drug, doctors are taking a more personalized approach by attempting to understand root causes of and the best treatments for diseases affecting cognitive decline, such as Alzheimer’s.